LYEL - Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting | Benzinga
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical?stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10.
One oral and two poster presentations will highlight data from Lyell's product pipeline and research programs, including:
- An oral presentation on Lyell's rejuvenation technology which has shown the potential to turn back the epigenetic clock to generate more stem-like T cells with reduced epigenetic age and enhanced proliferation ability
- A poster presentation of nonclinical data on LYL119, Lyell's second-generation ROR1-targeted CAR T-cell product candidate
- A poster presentation on technology being advanced through a collaboration between Lyell and Outpace to enable tumor-restricted IL-12 activity to enhance solid tumor T cell therapies
Details on the presentations are below.
An oral presentation titled "Rejuvenation of Tumor Infiltrating Lymphocytes: A novel strategy to revitalize TIL antitumor function for cell therapy" will highlight Lyell's rejuvenation technology which has shown the potential to generate T cells with reduced epigenetic age, more stem-like properties and enhanced proliferation ability. Previously published studies have demonstrated the decline in T-cell function as a person ages. These new nonclinical data show tumor infiltrating lympyocytes (TIL) rejuvenated with Lyell's technology retain a broad T-cell receptor repertoire and demonstrate sustained proliferation and improved antitumor activities in vivo.
Presentation details:
- Session Date/Time: Tuesday Apr 9, 2024 2:30 PM - 4:30 PM
- Abstract Number: 6593
- Session Category: Immunology
- Session Title: New Insights for Therapies Modulating Antitumor T-Cell Responses
New nonclinical data on LYL119, Lyell's second-generation ROR1-targeted CAR T-cell therapy, will be presented in a poster titled "LYL119, a Preclinical ROR1-Targeted CAR T-Cell Product Incorporating Four Novel Reprogramming Technologies Designed for Effective Cell Therapy for Solid Tumors." LYL119 incorporates four of Lyell's complementary, stackable T-cell reprogramming technologies and is designed to create potent ROR1-targeted CAR T cells with durable function. In this study, LYL119 demonstrated superior in vivo antitumor efficacy in a mouse xenograft tumor model across a 10-fold dose range, including at very low cell doses. In addition, following repeated rounds of tumor cell killing, LYL119, ...